Table 3.
Usefulness of cell type markers to predict durable response to pembrolizumab.
| Marker | Cell Type | AUC (95% CI) |
Sensitivity § (95% CI) * |
Specificity § (95% CI) * |
Accuracy (95% CI) * |
Correlation with PD-L1 **, R *** (p-Value) |
HR (95% CI), p-Value |
|---|---|---|---|---|---|---|---|
| CD244 | exhausted CD8 | 0.68 (0.52–0.84) |
0.84 (0.44–1) |
0.57 (0.29–0.95) |
0.72 (0.61–0.83) |
0.06 (0.71) | 0.65 (0.48–0.89), 0.007 |
| LAG3 | exhausted CD8 | 0.75 (0.61–0.89) |
0.68 (0.44–0.92) |
0.86 (0.57–1) |
0.76 (0.65–0.87) |
0.24 (0.11) | 0.66 (0.48–0.90), 0.009 |
| EOMES | exhausted CD8 | 0.82 (0.69–0.92) |
0.68 (0.44–1) |
0.95 (0.48–1) |
0.78 (0.67–0.89) |
0.25 (0.09) | 0.48 (0.34–0.67), 0.00002 |
| PTGER4 | exhausted CD8 | 0.75 (0.61–0.87) |
0.64 (0.40–1) |
0.90 (0.43–1) |
0.74 (0.63–0.85) |
0.03 (0.82) | 0.47 (0.27–0.81), 0.007 |
| CD8A | CD8 T-cell | 0.79 (0.66–0.91) |
0.68 (0.48–0.92) |
0.95 (0.71–1) |
0.78 (0.70–0.89) |
0.10 (0.51) | 0.61 (0.46–0.82), 0.001 |
| CD8B | CD8 T-cell | 0.82 (0.69–0.93) |
0.76 (0.56–0.96) |
0.86 (0.62–1) |
0.80 (0.70–0.91) |
0.13 (0.38) | 0.52 (0.38–0.73), 0.0001 |
| XCL1/2 | NK cell | 0.85 (0.74–0.95) |
0.88 (0.56–1) |
0.81 (0.57–1) |
0.83 (0.74–0.93) |
−0.08 (0.62) | 0.48 (0.34–0.66), 0.000007 |
| NCR1 | NK cell | 0.67 (0.51–0.82) |
0.88 (0.28–1) |
0.57 (0.38–1) |
0.72 (0.59–0.85) |
0.17 (0.26) | 0.75 (0.53–1.07), 0.12 |
| PD-L1 ** | NA | 0.61 (0.44–0.78) |
0.88 (0.20–1) |
0.43 (0.19–1) |
0.67 (0.54–0.78) |
NA | 0.99 (0.96–1.01), 0.32 |
* Sensitivity, specificity and accuracy were computed using the better cut-off according to the Youden’s J statistics. ** Exact percentage. *** R, Pearson’s correlation. § Sensitivity and specificity refer to the best cut-off according to the Youden J statistics. AUC, area under the curve; CI, confidence interval; NA, not applicable; HR, hazard ratio.